Description
EPO (Erythropoietin) is a 165-amino-acid glycoprotein synthesized primarily in the kidneys and functioning as the central regulator of erythropoiesis (erythrocyte formation in bone marrow). In research literature, EPO is one of the best-characterized growth factors at all, with extensive data on mechanism, pharmacokinetics and animal model effects.
The research mechanism lies in the activation of the EPO receptor on erythroid progenitor cells in the bone marrow. Binding leads to receptor dimerization, JAK2 activation and downstream STAT5 signaling, promoting the differentiation and survival of erythroid cells. Secondarily, EPO also activates other pathways in non-hematopoietic tissues, including the innate repair receptor (IRR), which mediates tissue-protective effects.
In preclinical studies, EPO has been comprehensively characterized in models of renal anemia, chemotherapy-induced anemia and chronic disease-associated anemia. Indeed, recombinant human EPO was one of the first successful biologic compounds and has a substantial research history.
In performance research context, EPO is interesting as a compound addressing erythrocyte mass and oxygen transport capacity. The data on effects on hematocrit, hemoglobin and endurance endpoints is extensive. EPO is among the prominent compounds in sports science, with clearly defined mechanisms and well-documented endpoints.
EPO is available in 4000iu vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
EPO is pharmacologically very well characterized as a growth factor, but it is among the more seriously rated compounds in this selection, because the increase in erythrocyte mass brings a direct and well-documented vascular risk.
Documented in the clinical literature and sports science:
- Hematocrit increase: EPO raises hematocrit through stimulation of erythropoiesis. The literature documents that an excessively high hematocrit substantially increases blood viscosity.
- Thromboembolism and stroke risk: the elevated hematocrit is clearly associated in clinical studies with an increased risk of thromboembolic events, including stroke. This is the central safety point with EPO.
- Blood pressure: clinical studies document blood pressure increases under EPO application.
- Injection site: redness or pressure at the injection site is among the more common observations.
- Difficult-to-control profile: the effect on hematocrit sets in with a delay and persists, which the literature describes as demanding to control.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Regulation of erythropoietin production - Journal of Physiology 2011: Review of regulation: EPO originates mainly from fibroblasts in the renal cortex, production is upregulated in hypoxia via the HIF transcription factors. Deficiency is the primary cause of anemia in chronic kidney disease.
- Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial - New England Journal of Medicine 1987: First clinical trial of recombinant EPO in 25 dialysis patients with renal anemia: dose-dependent increase in erythropoiesis, 12 of 18 patients no longer needed transfusions and four developed a rise in blood pressure.
- Effects of recombinant human erythropoietin in normal humans - Journal of Physiology 2011: Review of the effects in healthy humans: EPO raises arterial oxygen content through more red blood cells and a lower plasma volume and elevates arterial blood pressure even in healthy subjects.
- Correction of anemia with epoetin alfa in chronic kidney disease - New England Journal of Medicine 2006: Randomized trial in 1432 patients with chronic kidney disease: a higher hemoglobin target of 13.5 g/dl was associated with more cardiovascular events than 11.3 g/dl (hazard ratio 1.34), with no incremental improvement in quality of life.
- Emerging biological roles for erythropoietin in the nervous system - Nature Reviews Neuroscience 2005: Review of the non-hematopoietic effects: in preclinical models EPO is tissue protective via a distinct receptor, which led to engineered derivatives that do not stimulate erythropoiesis.
